Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 102

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 102
---
ITEM 4. INFORMATION ON THE COMPANY

A. History and Development of the Company

We were incorporated in British Columbia under
the name Cyntar Ventures Inc. on July 18, 2017, pursuant to the provisions of the Business Corporations Act(British Columbia).
On March 24, 2021, we changed our name to Clearmind Medicine Inc.

Originally, we operated as a mineral resource exploration
operations company. In September 2020, we announced a shift of the focus of our business to the development of innovative psychedelic
therapies. This process involved the acquisition of all rights, title and interests in several patent applications for the treatment of
alcohol abuse disorder and various other non-controlled binge behaviors. As part of this process, we announced a Change of Business, or
COB, listing on the Canadian Securities Exchange, or CSE. The COB became effective in November 2020. In May 2021, we completed all of
the requirements of the CSE for a COB listing. On March 14, 2024, we voluntarily delisted our Common Shares from the CSE.

Our principal executive offices are located at
101 - 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016. Our website address is https://www. clearmindmedicine. com/.
Information contained on or accessible through our website is not a part of this Annual Report on Form 20-F, and the inclusion of our
website address herein is an inactive textual reference only. Puglisi & Associates, or Puglisi, serves as our authorized representative
in the United States for certain limited matters. Puglisi’s address is 850 Library Avenue, Newark, Delaware 19711.

The SEC maintains an internet site that contains
reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at http://sec. gov.
We use our website ( http://www. clearmindmedicine. com), LinkedIn ( https://www. linkedin. com/company/clearmind-medicine), Instagram
( https://www. instagram. com/clearmindmed), Twitter ( https://twitter. com/ClearmindCMND) and Facebook ( https://www. facebook. com/ClearmindMedicine)
as channels of distribution of Company information. The information we post through this channel may be deemed material. Accordingly,
investors should monitor our